The Fox Chase Chemical Diversity Center, Inc. (FCCDC)

 

The Fox Chase Chemical Diversity Center is Pleased to Announce That it Has Been Awarded a Phase I STTR Entitled “Small Molecule Inhibitors of HIV1 Nef Virulence Factor for Treatment of HIV/AIDS”

 

Doylestown, PA. September 3, 2014- FCCDC is pleased to announce that it has been awarded a Phase I STTR entitled “Small Molecule Inhibitors of HIV1 Nef Virulence Factor for Treatment of HIV/AIDS” (R41 GM112516-01, $225,000).  The Principal Investigator is Prof. Thomas Smithgall of the University of Pittsburgh.